Clinical Trials Browser

Breast Neoplasms

NCT07391774 2026-04-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Phase 3 Not yet recruiting

1,978 enrolled

Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT07518173 2026-04-08

A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer

Phase 3 Not yet recruiting

596 enrolled

Breast

HER2-positive Breast Cancer

NCT05379153 2026-04-07

Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial

Phase 3 Not yet recruiting

250 enrolled

Breast

Breast Carcinoma In Situ

NCT07340658 2026-04-02

SIE-3

Phase 3 Not yet recruiting

300 enrolled

Breast

Breast Neoplasms

NCT07432178 2026-04-02

CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）

Phase 3 Not yet recruiting

2,288 enrolled

Breast

Breast Neoplasms

NCT07502820 2026-03-31

POWER

Phase 3 Not yet recruiting

1,100 enrolled

Breast

Breast Neoplasms

NCT07492641 2026-03-25

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

Phase 3 Not yet recruiting

1,056 enrolled

Breast

HR+/HER2- Breast Cancer

NCT07106632 2026-03-24

OPTIMA-YOUNG

Phase 3 Not yet recruiting

3,380 enrolled

Breast

Breast Neoplasms

NCT07486687 2026-03-20

PLANET

Phase 3 Not yet recruiting

1,000 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07483996 2026-03-19

CRYSTAL

Phase 3 Not yet recruiting

938 enrolled

Breast

Breast Neoplasms

NCT07461454 2026-03-10

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

Phase 3 Not yet recruiting

376 enrolled

Breast

Breast Neoplasms

NCT07406542 2026-02-12

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

Phase 3 Not yet recruiting

400 enrolled

Breast

Breast Neoplasms, Recurrence

NCT07407517 2026-02-12

POLARIS

Phase 3 Not yet recruiting

904 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07385365 2026-02-11

A Study of Postoperative Regional Nodal Radiotherapy in Intermediate-risk Breast Cancer

Phase 3 Not yet recruiting

3,142 enrolled

Breast

Breast Neoplasms

NCT07393321 2026-02-06

A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer

Phase 3 Not yet recruiting

210 enrolled

Breast

Breast Neoplasms

NCT07382687 2026-02-03

Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype

Phase 3 Not yet recruiting

248 enrolled

Breast

Breast Neoplasms

NCT07372144 2026-01-28

IARA

Phase 3 Not yet recruiting

227 enrolled

Breast

Breast Neoplasms

NCT07357298 2026-01-22

Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer

Phase 3 Not yet recruiting

156 enrolled

Breast

Breast Neoplasms

NCT07269691 2025-12-08

RaSOLVE: 125I Radioactive Seed Marking Effects on Pathological Complete Response Rate and Prognosis Post-Neoadjuvant Therapy in Early/Advanced Breast Cancer

Phase 3 Not yet recruiting

194 enrolled

Breast

Breast Neoplasms

NCT06787118 2025-12-02

PANDORA

Phase 3 Not yet recruiting

130 enrolled

Breast

Breast Neoplasms

NCT07242352 2025-11-21

ADAPTela

Phase 3 Not yet recruiting

1,520 enrolled

Breast

Breast Neoplasms

NCT07239271 2025-11-20

A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation Model

Phase 3 Not yet recruiting

2,000 enrolled

Breast

Patients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy

NCT07213206 2025-10-08

Cinderella

Phase 3 Not yet recruiting

1,500 enrolled

Breast

Breast Neoplasms

NCT07178730 2025-09-17

ADAPT-TN-IV

Phase 3 Not yet recruiting

765 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07153757 2025-09-04

DESCENT

Phase 3 Not yet recruiting

2,934 enrolled

Breast

Breast Cancer Early Stage Breast Cancer (Stage 1-3)

NCT07084519 2025-07-24

Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction

Phase 3 Not yet recruiting

190 enrolled

Breast

Breast Neoplasms

NCT06835400 2025-07-11

Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer

Phase 3 Not yet recruiting

340 enrolled

Breast

Breast Neoplasms

NCT07061717 2025-07-11

Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

Phase 3 Not yet recruiting

474 enrolled

Breast

Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

NCT06434077 2025-06-22

Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Breast Cancer

Phase 3 Not yet recruiting

60 enrolled

Breast

Breast Neoplasms

NCT07021261 2025-06-13

Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients

Phase 3 Not yet recruiting

440 enrolled

Breast

Breast Neoplasms

NCT07005557 2025-06-05

SENIOR

Phase 3 Not yet recruiting

1,244 enrolled

Breast

Breast Neoplasms

NCT06996093 2025-05-30

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

Phase 3 Not yet recruiting

2,508 enrolled

Breast

Breast Neoplasms

NCT06223698 2025-04-20

SWE-Switch

Phase 3 Not yet recruiting

3,832 enrolled

Breast

Breast Neoplasms

NCT06929325 2025-04-16

Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors

Phase 3 Not yet recruiting

312 enrolled

Breast

Breast Neoplasms

NCT06811220 2025-02-06

The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients

Phase 3 Not yet recruiting

140 enrolled

Breast

Breast Neoplasms

NCT06795503 2025-01-28

Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients

Phase 3 Not yet recruiting

1,462 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06774885 2025-01-14

ROLE OF FOLIC ACID IN THE MANAGEMENT OF ADJUVANT ENDOCRINE THERAPY-INDUCED HOT FLASHES IN BREAST CANCER PATIENTS

Phase 3 Not yet recruiting

120 enrolled

Breast

Breast Neoplasms, Hot Flashes

NCT06611514 2024-11-19

PROPOSE

Phase 3 Not yet recruiting

95 enrolled

Breast

Breast Neoplasms

NCT06407401 2024-11-05

Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer

Phase 3 Not yet recruiting

399 enrolled

Breast

Breast Neoplasms, Musculoskeletal Pain, Drug-Related Side Effects and Adverse Reactions

NCT06561607 2024-08-20

A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

Phase 3 Not yet recruiting

542 enrolled

Breast

Breast Neoplasms

NCT06270355 2024-02-28

SMART

Phase 3 Not yet recruiting

70,000 enrolled

Breast

Breast Neoplasms

NCT05993559 2024-01-12

Necessity of Post-mastectomy Radiotherapy After Neoadjuvant Chemotherapy and Mastectomy

Phase 3 Not yet recruiting

1,314 enrolled

Breast

Breast Neoplasms

NCT05901935 2023-06-13

DP303c in Patients With HER2-positive Advanced Breast Cancer

Phase 3 Not yet recruiting

420 enrolled

Breast

HER2-positive Advanced Breast Cancer

NCT05889871 2023-06-05

A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer

Phase 3 Not yet recruiting

916 enrolled

Breast

HR+/HER2-breast Cancer

NCT05841381 2023-05-03

Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer

Phase 3 Not yet recruiting

876 enrolled

Breast

Breast Neoplasms

NCT05698186 2023-01-26

Thero2-01S22 in HER2-positive Breast Cancer

Phase 3 Not yet recruiting

320 enrolled

Breast

HER2-positive Breast Cancer

NCT05388500 2022-05-27

PHARE-C

Phase 3 Not yet recruiting

800 enrolled

Breast

HER2-positive Breast Cancer

NCT05253170 2022-03-11

Hypo Versus Conventional Fractionation in Reconstructed-Breast Cancer Mastectomy Patients

Phase 3 Not yet recruiting

622 enrolled

Breast

Breast Neoplasms

NCT05172518 2021-12-29

Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer

Phase 3 Not yet recruiting

512 enrolled

Breast

Breast Neoplasms

Clinical Trials

Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer

Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial

SIE-3

CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）

POWER

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

OPTIMA-YOUNG

PLANET

CRYSTAL

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

POLARIS

A Study of Postoperative Regional Nodal Radiotherapy in Intermediate-risk Breast Cancer

A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer

Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype

IARA

Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer

RaSOLVE: 125I Radioactive Seed Marking Effects on Pathological Complete Response Rate and Prognosis Post-Neoadjuvant Therapy in Early/Advanced Breast Cancer

PANDORA

ADAPTela

A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation Model

Cinderella

ADAPT-TN-IV

DESCENT

Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction

Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer

Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Breast Cancer

Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients

SENIOR

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

SWE-Switch

Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors

The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients

Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients

ROLE OF FOLIC ACID IN THE MANAGEMENT OF ADJUVANT ENDOCRINE THERAPY-INDUCED HOT FLASHES IN BREAST CANCER PATIENTS

PROPOSE

Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer

A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

SMART

Necessity of Post-mastectomy Radiotherapy After Neoadjuvant Chemotherapy and Mastectomy

DP303c in Patients With HER2-positive Advanced Breast Cancer

A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer

Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer

Thero2-01S22 in HER2-positive Breast Cancer

PHARE-C

Hypo Versus Conventional Fractionation in Reconstructed-Breast Cancer Mastectomy Patients

Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer